Company Encyclopedia
View More
name
CDBIO
688739.SH
Liaoning Chengda Biotechnology Co.,Ltd. a biotechnology company, engages in the research and development, production, and sales of vaccines for human use worldwide. It offers inactivated Japanese encephalitis vaccine (IJEV) and SPEEDA-rabies vaccine. The company’s rabies and influenza vaccines are in the new drug application stage; haemophilus influenzae type b vaccine in phase III; recombinant human papillomavirus 15-valent vaccine is in phase II; and 13-valent pneumococcal polysaccharide conjugate and varicella, as well as the live meningococcal A, C, Y and W-135 conjugate vaccine are in phase I.
1.557 T
688739.SHMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
C
BiotechnologyIndustry
Industry Ranking36/81
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.88%C
    • Profit Margin12.11%B
    • Gross Margin84.03%A
  • Growth ScoreD
    • Revenue YoY-14.47%E
    • Net Profit YoY-46.42%D
    • Total Assets YoY-2.30%D
    • Net Assets YoY-1.70%D
  • Cash ScoreC
    • Cash Flow Margin825.83%B
    • OCF YoY-14.47%E
  • Operating ScoreD
    • Turnover0.15D
  • Debt ScoreA
    • Gearing Ratio4.24%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    CDBIO signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences

    CDBIO signed a strategic cooperation agreement with the Institute of Microbiology, Chinese Academy of Sciences, focusing on emerging infectious diseases, particularly the prevention of vector-borne diseases. Both parties will jointly apply for research projects and collaborate to respond to infectious disease prevention and control. This agreement is a letter of intent for cooperation and does not have a direct impact on the performance for the year 2025 and beyond; the specific impact will depend on the progress of subsequent projects

    Zhitong·
    SH
    688739
    -0.42%
    Zhitong·
    SH
    688739
    -0.42%

    CDBIO disclosed the progress of its share repurchase, with a total repurchase amount of nearly 10.8 million yuan

    Liaoning CDBIO Co., Ltd. disclosed the progress of its share repurchase. Since the initial announcement of the repurchase plan on June 19, 2025, as of September 30, 2025, the company has repurchased a total of 384,899 shares, with a total payment of approximately 10,789,216.56 yuan, and the repurchase price ranged from 27.20 yuan to 29.61 yuan. The expected amount for the repurchase plan is between 10 million and 20 million yuan, mainly for the employee stock ownership plan or equity incentives. The company will continue to promote the repurchase and disclose relevant information in a timely manner

    Zhitong·
    SH
    688739
    -0.42%
    Zhitong·
    SH
    688739
    -0.42%

    CDBIO: Net profit of 122 million yuan in the first half of 2025, a year-on-year decrease of 44.47%

    CDBIO announced that its operating revenue in the first half of 2025 was 707 million yuan, a year-on-year decrease of 19.75%. Net profit was 122 million yuan, a year-on-year decrease of 44.47%

    Zhitong·
    SH
    688739
    -0.42%
    Zhitong·
    SH
    688739
    -0.42%

    CDBIO Chairman proposes to repurchase company shares worth 10 million to 20 million yuan

    According to the Zhitong Finance APP, CDBIO announced that based on a strong confidence in the company's long-term development strategy and a full recognition of its intrinsic value, the company's chairman, Mr. Li Ning, proposed that the company repurchase a portion of its shares through centralized bidding trading, to be used for implementing an employee stock ownership plan or equity incentive at an appropriate time in the future. The total amount of funds for this repurchase will not be less than RMB 10 million (inclusive) and will not exceed RMB 20 million (inclusive)

    Zhitong·
    SH
    688739
    -0.42%
    Zhitong·
    SH
    688739
    -0.42%

    CDBIO released its first-quarter performance, with a net profit attributable to the parent company of 72.22 million yuan, a year-on-year decrease of 11.35%

    According to the Zhitong Finance APP, CDBIO disclosed its first-quarter report for 2025, showing that the company achieved revenue of 358 million yuan during the reporting period, a year-on-year decrease of 1.73%; net profit attributable to the parent company was 72.22 million yuan, a year-on-year decrease of 11.35%; and net profit excluding non-recurring items was 62.57 million yuan, a year-on-year decrease of 8.45%. The basic earnings per share were 0.18 yuan

    Zhitong·
    SH
    688739
    -0.42%
    Zhitong·
    SH
    688739
    -0.42%
    © 2025 Longbridge｜Disclaimer